Jaguar Health (JAGX)
Jaguar Health on one page: short interest, daily short volume, fails to deliver, large holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
141K
Short interest
settlement 2026-10-15
1.0
Days to cover
unchanged vs prior
35.2%
Short share of volume
2026-11-02
12,921
Fails to deliver
settlement 2026-10-14
Wed 11 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in JAGX is 140,557 shares, down 185,575 shares over the last month. Over the last 48 readings it ranged from 23,167 shares (30 June 2025) to 953,074 shares (28 February 2025). At the reported average volume of 5.0M shares a day that is 1.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/jagx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 140,557 | +67.0% | 4,969,953 | 1.00 |
| 2026-09-30 | 84,156 | -74.2% | 6,733,241 | 1.00 |
| 2026-09-15 | 326,132 | +34.8% | 827,180 | 1.00 |
| 2026-08-31 | 242,001 | +106.8% | 151,797 | 1.59 |
| 2026-08-14 | 117,037 | +34.3% | 228,358 | 1.00 |
| 2026-07-31 | 87,153 | +68.6% | 119,074 | 1.00 |
| 2026-07-15 | 51,687 | -30.0% | 34,118 | 1.51 |
| 2026-06-30 | 73,828 | +34.0% | 122,903 | 1.00 |
| 2026-06-15 | 55,091 | -14.0% | 53,788 | 1.02 |
| 2026-05-29 | 64,056 | -5.1% | 166,303 | 1.00 |
| 2026-05-15 | 67,479 | -37.3% | 156,723 | 1.00 |
| 2026-04-30 | 107,543 | -82.1% | 19,736 | 5.45 |
| 2026-04-15 | 599,897 | +24.6% | 686,294 | 1.00 |
| 2026-03-31 | 481,255 | +10.8% | 323,666 | 1.49 |
| 2026-03-13 | 434,273 | +32.6% | 662,873 | 1.00 |
| 2026-02-27 | 327,563 | -15.2% | 392,756 | 1.00 |
| 2026-02-13 | 386,035 | -23.1% | 357,684 | 1.08 |
| 2026-01-30 | 502,013 | -9.1% | 17,948,104 | 1.00 |
| 2026-01-15 | 552,389 | +99.4% | 3,207,496 | 1.00 |
| 2025-12-31 | 277,020 | +12.8% | 164,152 | 1.69 |
| 2025-12-15 | 245,697 | +227.7% | 566,481 | 1.00 |
| 2025-11-28 | 74,987 | -26.9% | 161,960 | 1.00 |
| 2025-11-14 | 102,632 | +147.1% | 94,159 | 1.09 |
| 2025-10-31 | 41,543 | -31.9% | 60,236 | 1.00 |
| 2025-10-15 | 61,045 | -21.4% | 194,391 | 1.00 |
| 2025-09-30 | 77,686 | +112.8% | 225,353 | 1.00 |
| 2025-09-15 | 36,502 | -44.8% | 114,851 | 1.00 |
| 2025-08-29 | 66,131 | +114.1% | 168,237 | 1.00 |
| 2025-08-15 | 30,894 | -29.8% | 103,665 | 1.00 |
| 2025-07-31 | 44,024 | +11.1% | 90,177 | 1.00 |
| 2025-07-15 | 39,637 | +71.1% | 93,131 | 1.00 |
| 2025-06-30 | 23,167 | -32.2% | 98,704 | 1.00 |
| 2025-06-13 | 34,177 | +18.7% | 77,431 | 1.00 |
| 2025-05-30 | 28,785 | -10.8% | 133,196 | 1.00 |
| 2025-05-15 | 32,263 | -71.8% | 85,739 | 1.00 |
| 2025-04-30 | 114,446 | +114.9% | 412,097 | 1.00 |
| 2025-04-15 | 53,245 | +4.3% | 79,547 | 1.00 |
| 2025-03-31 | 51,062 | -94.3% | 58,540 | 1.00 |
| 2025-03-14 | 891,219 | -6.5% | 290,350 | 3.07 |
| 2025-02-28 | 953,074 | +49.7% | 548,898 | 1.74 |
| 2025-02-14 | 636,664 | -18.9% | 253,318 | 2.51 |
| 2025-01-31 | 785,103 | +32.5% | 283,871 | 2.77 |
| 2025-01-15 | 592,656 | +19.1% | 683,000 | 1.00 |
| 2024-12-31 | 497,706 | -26.5% | 488,778 | 1.02 |
| 2024-12-13 | 677,131 | +31.4% | 671,956 | 1.01 |
| 2024-11-29 | 515,259 | +19.6% | 148,363 | 3.47 |
| 2024-11-15 | 430,733 | +29.6% | 333,629 | 1.29 |
| 2024-10-31 | 332,319 | +138.4% | 268,049 | 1.24 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of JAGX volume is 35.2%, down 24.0 points over the last five sessions. Over the last 30 readings it ranged from 33.7% (23 October 2026) to 64.5% (25 September 2026). The latest reading sits at the bottom of that range. The latest reading is 15.4 points below the 30-session average of 50.6%, on 881K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 310K | 881K | 35.2% | 101,078 |
| 2026-10-30 | 117K | 187K | 62.5% | 21,515 |
| 2026-10-29 | 49K | 131K | 37.5% | 0 |
| 2026-10-28 | 65K | 128K | 50.8% | 6,682 |
| 2026-10-27 | 43K | 119K | 35.8% | 15 |
| 2026-10-26 | 947K | 1.6M | 59.2% | 16,904 |
| 2026-10-23 | 23K | 68K | 33.7% | 3 |
| 2026-10-22 | 48K | 92K | 52.5% | 17,003 |
| 2026-10-21 | 99K | 247K | 40.1% | 10,392 |
| 2026-10-20 | 46K | 113K | 40.5% | 3,989 |
| 2026-10-19 | 151K | 271K | 55.8% | 40,867 |
| 2026-10-16 | 179K | 369K | 48.6% | 55,473 |
| 2026-10-15 | 100K | 242K | 41.5% | 7,609 |
| 2026-10-14 | 128K | 259K | 49.4% | 17,347 |
| 2026-10-13 | 116K | 231K | 50.3% | 7,446 |
| 2026-10-12 | 142K | 229K | 61.9% | 3,664 |
| 2026-10-09 | 390K | 708K | 55.1% | 106,871 |
| 2026-10-08 | 115K | 321K | 35.9% | 35,293 |
| 2026-10-07 | 321K | 608K | 52.8% | 58,136 |
| 2026-10-06 | 5.4M | 9.5M | 57.1% | 47,279 |
| 2026-10-05 | 4.6M | 8.1M | 56.5% | 806,990 |
| 2026-10-02 | 132K | 288K | 46.0% | 19,340 |
| 2026-10-01 | 84K | 184K | 45.5% | 14,684 |
| 2026-09-30 | 150K | 269K | 55.9% | 29,951 |
| 2026-09-29 | 208K | 345K | 60.3% | 44,293 |
| 2026-09-28 | 276K | 539K | 51.3% | 72,364 |
| 2026-09-25 | 7.1M | 11.1M | 64.5% | 1,619,131 |
| 2026-09-24 | 530K | 872K | 60.7% | 133,667 |
| 2026-09-23 | 2.2M | 3.7M | 61.1% | 515,208 |
| 2026-09-22 | 7.6M | 12.7M | 59.4% | 56,285 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in JAGX is 12,921 shares, down 33,393 shares over the last settlement date. Over the last 30 readings it ranged from 661 shares (24 August 2026) to 129,472 shares (8 October 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 12,921 | $4.16 | $54K |
| 2026-10-13 | 46,314 | $4.64 | $215K |
| 2026-10-09 | 65,333 | $4.53 | $296K |
| 2026-10-08 | 129,472 | $5.00 | $647K |
| 2026-10-07 | 84,293 | $5.62 | $474K |
| 2026-10-06 | 57,011 | $4.73 | $270K |
| 2026-10-02 | 2,065 | $3.95 | $8K |
| 2026-09-30 | 861 | $5.32 | $5K |
| 2026-09-29 | 6,287 | $6.02 | $38K |
| 2026-09-28 | 35,615 | $7.70 | $274K |
| 2026-09-25 | 1,323 | $7.06 | $9K |
| 2026-09-24 | 22,992 | $8.91 | $205K |
| 2026-09-23 | 41,549 | $34.46 | $1.4M |
| 2026-09-22 | 7,104 | $2.67 | $19K |
| 2026-09-21 | 2,764 | $2.71 | $7K |
| 2026-09-18 | 5,778 | $2.75 | $16K |
| 2026-09-16 | 866 | $0.22 | $191 |
| 2026-09-15 | 11,553 | $0.32 | $4K |
| 2026-09-14 | 10,902 | $0.31 | $3K |
| 2026-09-11 | 9,678 | $0.32 | $3K |
| 2026-09-10 | 11,000 | $0.37 | $4K |
| 2026-09-09 | 4,028 | $0.41 | $2K |
| 2026-09-08 | 1,072 | $0.60 | $643 |
| 2026-09-03 | 5,040 | $0.73 | $4K |
| 2026-09-02 | 14,276 | $0.73 | $10K |
| 2026-09-01 | 26,564 | $0.79 | $21K |
| 2026-08-31 | 24,366 | $0.81 | $20K |
| 2026-08-28 | 16,278 | $0.87 | $14K |
| 2026-08-27 | 12,381 | $0.92 | $11K |
| 2026-08-24 | 661 | $0.87 | $575 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for JAGX in the last 90 days. The most recent filings are listed below. Latest filing: Siegel Jonathan B. (Director) on 2025-12-11.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | Siegel Jonathan B. | Director | Grant | 7K | $0.00 | $0 | 7K |
| 2025-12-11 | Jayasuriya Anula | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2025-12-11 | Lizak Carol R. | Chief Financial Officer | Grant | 12K | $0.00 | $0 | 12K |
| 2025-12-11 | Chaturvedi Pravin R | Chief Scientific Officer | Grant | 12K | $0.00 | $0 | 12K |
| 2025-12-11 | BOCHNOWSKI JAMES J | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2025-12-11 | King Steven R. | See Remarks | Grant | 12K | $0.00 | $0 | 12K |
| 2025-12-11 | Wolin Jonathan S. | See Remarks | Grant | 12K | $0.00 | $0 | 12K |
| 2025-12-11 | CONTE LISA A | See Remarks | Grant | 29K | $0.00 | $0 | 29K |
| 2025-12-11 | MICEK JOHN | Director | Grant | 7K | $0.00 | $0 | 7K |
| 2025-05-17 | CONTE LISA A | CEO and President | Exercise or conversion | 2 | price not stated in the filing | not stated | 666 |
| 2025-05-17 | King Steven R. | See Remarks | Exercise or conversion | 1 | price not stated in the filing | not stated | 145 |
| 2024-10-08 | King Steven R. | See Remarks | Grant | 5K | $0.00 | $0 | 5K |
| 2024-10-08 | CONTE LISA A | See Remarks | Grant | 17K | $0.00 | $0 | 17K |
| 2024-10-08 | Wolin Jonathan S. | See Remarks | Grant | 5K | $0.00 | $0 | 5K |
| 2024-10-08 | Chaturvedi Pravin R | Chief Scientific Officer | Grant | 5K | $0.00 | $0 | 5K |
| 2024-10-08 | Lizak Carol R. | Chief Financial Officer | Grant | 4K | $0.00 | $0 | 4K |
| 2024-05-17 | CONTE LISA A | CEO and President | Exercise or conversion | 3K | price not stated in the filing | not stated | 7K |
| 2024-05-17 | King Steven R. | See Remarks | Exercise or conversion | 612 | price not stated in the filing | not stated | 2K |
| 2024-05-17 | Lizak Carol R. | Chief Financial Officer | Exercise or conversion | 431 | price not stated in the filing | not stated | 1K |
| 2024-05-17 | Wolin Jonathan S. | Chief of Staff, CCO & GC | Exercise or conversion | 871 | price not stated in the filing | not stated | 2K |
| 2024-05-17 | Chaturvedi Pravin R | Chief Scientific Officer | Exercise or conversion | 871 | price not stated in the filing | not stated | 2K |
| 2024-04-05 | CONTE LISA A | CEO and President | Exercise or conversion | 600 | price not stated in the filing | not stated | 5K |
| 2024-04-05 | King Steven R. | See Remarks | Exercise or conversion | 178 | price not stated in the filing | not stated | 1K |
| 2024-04-05 | Lizak Carol R. | Chief Financial Officer | Exercise or conversion | 60 | price not stated in the filing | not stated | 611 |
| 2024-04-05 | Wolin Jonathan S. | Chief of Staff, CCO & GC | Exercise or conversion | 89 | price not stated in the filing | not stated | 1K |
| 2024-04-05 | Chaturvedi Pravin R | Chief Scientific Officer | Exercise or conversion | 134 | price not stated in the filing | not stated | 1K |
| 2023-08-14 | CONTE LISA A | CEO and President | Grant | 384K | $0.00 | $0 | 388K |
| 2023-08-14 | King Steven R. | see remarks | Grant | 159K | $0.00 | $0 | 160K |
| 2023-08-14 | Lizak Carol R. | Chief Financial Officer | Grant | 142K | $0.00 | $0 | 143K |
| 2023-08-14 | Wolin Jonathan S. | Chief of Staff, CCO & GC | Grant | 197K | $0.00 | $0 | 198K |
| 2023-08-14 | Chaturvedi Pravin R | Chief Scientific Officer | Grant | 204K | $0.00 | $0 | 205K |
| 2023-08-14 | BOCHNOWSKI JAMES J | Director | Grant | 77K | $0.00 | $0 | 79K |
| 2023-08-14 | MICEK JOHN | Director | Grant | 69K | $0.00 | $0 | 81K |
| 2023-08-14 | Siegel Jonathan B. | Director | Grant | 69K | $0.00 | $0 | 70K |
| 2023-08-14 | Jayasuriya Anula | Director | Grant | 69K | $0.00 | $0 | 70K |
| 2023-07-01 | Jayasuriya Anula | Director | Grant | 2K | $0.00 | $0 | 2K |
| 2023-05-17 | CONTE LISA A | CEO and President | Exercise or conversion | 3K | price not stated in the filing | not stated | 4K |
| 2023-05-17 | King Steven R. | Chief of Sustainable Supply | Exercise or conversion | 611 | price not stated in the filing | not stated | 965 |
| 2023-05-17 | Lizak Carol R. | Chief Financial Officer | Exercise or conversion | 431 | price not stated in the filing | not stated | 657 |
| 2023-05-17 | Wolin Jonathan S. | Chief of Staff, CCO & GC | Exercise or conversion | 871 | price not stated in the filing | not stated | 1K |
| 2023-05-17 | BOCHNOWSKI JAMES J | Director | Exercise or conversion | 1K | price not stated in the filing | not stated | 2K |
| 2023-05-17 | MICEK JOHN | Director | Exercise or conversion | 1K | price not stated in the filing | not stated | 1K |
| 2023-05-17 | Siegel Jonathan B. | Director | Exercise or conversion | 1K | price not stated in the filing | not stated | 1K |
| 2023-05-17 | Chaturvedi Pravin R | Chief Scientific Officer | Exercise or conversion | 870 | price not stated in the filing | not stated | 1K |
| 2023-04-05 | CONTE LISA A | CEO and President | Exercise or conversion | 600 | price not stated in the filing | not stated | 1K |
| 2023-04-05 | King Steven R. | Chief of Sustainable Supply | Exercise or conversion | 177 | price not stated in the filing | not stated | 354 |
| 2023-04-05 | Wolin Jonathan S. | Chief of Staff, CCO & GC | Exercise or conversion | 88 | price not stated in the filing | not stated | 181 |
| 2023-04-05 | Lizak Carol R. | Chief Financial Officer | Exercise or conversion | 60 | price not stated in the filing | not stated | 226 |
| 2023-04-05 | Chaturvedi Pravin R | Chief Scientific Officer | Exercise or conversion | 44 | price not stated in the filing | not stated | 88 |
| 2023-04-05 | Chaturvedi Pravin R | Chief Scientific Officer | Exercise or conversion | 133 | price not stated in the filing | not stated | 266 |
| 2022-12-31 | Wolin Jonathan S. | Chief of Staff, CCO & GC | Buy | 317 | $0.03 | $10 | 7K |
| 2022-05-18 | BOCHNOWSKI JAMES J | Director | Exercise or conversion | 13K | price not stated in the filing | not stated | 74K |
| 2022-05-18 | MICEK JOHN | Director | Exercise or conversion | 12K | price not stated in the filing | not stated | 12K |
| 2022-05-18 | Siegel Jonathan B. | Director | Exercise or conversion | 12K | price not stated in the filing | not stated | 12K |
| 2022-05-18 | Divis Gregory J | Director | Exercise or conversion | 12K | price not stated in the filing | not stated | 12K |
| 2022-04-05 | Chaturvedi Pravin R | Chief Scientific Officer | Exercise or conversion | 10K | price not stated in the filing | not stated | 10K |
| 2022-04-05 | CONTE LISA A | CEO and President | Exercise or conversion | 45K | price not stated in the filing | not stated | 53K |
| 2022-04-05 | King Steven R. | Chief of Sustainable Supply | Exercise or conversion | 13K | price not stated in the filing | not stated | 13K |
| 2022-04-05 | Wolin Jonathan S. | Chief of Staff, CCO & GC | Exercise or conversion | 7K | price not stated in the filing | not stated | 7K |
| 2022-04-05 | Lizak Carol R. | Chief Financial Officer | Exercise or conversion | 5K | price not stated in the filing | not stated | 12K |
| 2022-04-05 | Chaturvedi Pravin R | Chief Scientific Officer | Exercise or conversion | 3K | price not stated in the filing | not stated | 3K |
| 2021-09-13 | CONTE LISA A | CEO and President | Buy | 8K | $2.51 | $20K | 8K |
| 2021-09-13 | Lizak Carol R. | Chief Financial Officer | Buy | 8K | $2.51 | $20K | 8K |
| 2021-06-04 | BOCHNOWSKI JAMES J | Director | Sell | 152 | $1.74 | $264 | 954K |
| 2021-06-03 | BOCHNOWSKI JAMES J | Director | Sell | 292 | $1.75 | $511 | 955K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of JAGX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Joshua Mailman at 10.0% of the class (189,617 shares), filed 2026-09-24 for an event on 2026-09-12.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-24 | 13G/Ano. 1 | Joshua Mailmanindividual | 190K | 10.0% | 2026-09-12 |
| 2026-02-10 | 13G/Ano. 1 | Lincoln Alternative Strategies LLCother entity | 0 | 0.0% | 2026-01-12 |
| 2025-12-11 | 13G/Ano. 1 | Streeterville Capital LLCother entity | 0 | 0.0% | 2025-12-11 |
| 2025-12-11 | 13G/Ano. 1 | Streeterville Management, LLCother entity | 0 | 0.0% | 2025-12-11 |
| 2025-12-11 | 13G/Ano. 1 | John M. Fifeindividual | 0 | 0.0% | 2025-12-11 |
| 2025-12-11 | 13G | Iliad Research & Trading, L.P.partnership | 440K | 9.8% | 2025-12-11 |
| 2025-12-11 | 13G | Iliad Management, LLCother entity | 440K | 9.8% | 2025-12-11 |
| 2025-12-11 | 13G | Fife Trading, Inc.other entity | 440K | 9.8% | 2025-12-11 |
| 2025-11-07 | 13G/Ano. 3 | CVI Investments, Inc.corporation | 164K | 4.6% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 3 | Heights Capital Management, Inc.corporation | 164K | 4.6% | 2025-09-30 |
What this page is
Jaguar Health in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Jaguar Health (JAGX), SEC CIK 1585608, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-24.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-19.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2025-12-11.JSON and CSV
- Company record
- EDGAR filing index for CIK 1585608Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of JAGX is sold short?
140,557 shares were held short at the 2026-10-15 settlement, 1.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is JAGX's daily short volume?
On 2026-11-02, 309,905 of the 881,121 JAGX shares reported to FINRA were sold short, 35.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does JAGX have fails to deliver?
The SEC's latest file shows 12,921 JAGX shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are JAGX insiders buying or selling?
No open-market insider trades were reported for JAGX in the last 90 days. The most recent filings are listed below. Latest filing: Siegel Jonathan B. (Director) on 2025-12-11.
Who owns 5% or more of JAGX?
4 holders report 5% or more of JAGX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Joshua Mailman at 10.0% of the class (189,617 shares), filed 2026-09-24 for an event on 2026-09-12.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.